P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)

P1.01A.02 Monitoring Inflammatory Response Secondary to Air Pollution Exposure Through Volatile Organic Compounds

P1.01A.03 Can-Prevent-Lung Trial-Canakinumab for the Prevention of Lung Cancer: Updated Interim Clinical and Biomarker Analysis

P1.01B.02 The Genomic Landscape of Lung Cancer in Never-Smokers from the Women's Health Initiative

P1.01B.03 Risk Factors Associated with Venous Thromboembolism in Advanced ALK Rearranged Non-Small Cell Lung Cancer

P1.01B.04 A Highly Unmet Need: Patterns of Lung Cancer Screening in Head and Neck Cancer Survivors Preceding a Lung Cancer Diagnosis

P1.01B.05 Real-World Data on 3-Year Survival in Non-Small Cell Lung Cancer (NSCLC): Results from 3 French Nationwide Cohorts from 2000 To 2020

P1.01C.01 Effectiveness of Health Education on Adolescent Tobacco Use Intention: Cluster RCT in Ibadan, Nigeria

P1.01C.02 Tobacco Control and Smoking Cessation-related Content in Oncology Meetings: A Scoping Review

P1.01C.03 The Influence of Smoking on Morbidity and Early Mortality after Anatomical Lung Resections for Stage I-IIIA NSCLC

P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop

P1.01C.05 Potential Impact of Tobacco Control Policies in Preventing Incident Lung Cancers in the Eastern Mediterranean Region

P1.02A.01 ADAR1 Regulates Tumorigenesis and Stem Cell Properties in Non-Small Cell Lung Carcinoma

P1.02B.01 Mirnome Functional Profiling of Non-Small Cell Lung Cancer Identified New Mechanisms of PD-L1 Regulation

P1.02C.02 NIR-II Mediates Cancer Nanocomposite Vaccines for Lymph Node Targeted Delivery and Enhanced Immunotherapy

P1.02D.02 Tumor-Derived Exosomal tsRNA 3’ tiRNA-AlaCGC Promotes Immune Tolerance by Inducing Fibroblast Senescence in LUAD

P1.03A.01 Identification of Disulfidptosis in ESCC Based on Single-Cell and Bulk RNA-seq Data to Predict Prognosis and Treatment Response

P1.03A.02 FBXO32 Promotes EMT and Regulates the Cell Cycle by Targeting PTEN for Proteasomal-Dependent Degradation in LUAD

P1.03B.01 Multi-Omics Profiling Reveals the Genomic Origin and Adeno-Squamous Transdifferentiation Mechanism in Adenosquamous Carcinoma

P1.03C.01 A Landscape of the Driver Alterations in 920 Brazilian Lung Cancer Patients.

P1.03C.02 Different STK11 Mutation Status Defines Various TIME in NSCLC

P1.03D.02 An Enhanced Immunotherapeutic Strategie for NSCLC via in Situ Tumor Nanovaccines and Activation of STING and TLR7/8 Pathways

P1.03D.03 Artemisinin Enhances Anti-Tumor Immunity by Increasing FGL1 Ubiquitination Degradation via Activating TRIM21 In NSCLC

P1.03D.04 Circulating APOBEC Signature as a Non-Invasive Biomarker Delineating Potential Responder to Neoadjuvant Immunotherapy for IIIA-N2 NSCLC

P1.03D.05 A Novel DNA Repair-Gene Model to Predict Responses to Immunotherapy and Prognosis in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

P1.03D.07 Overcoming Immunotherapy Resistance in Non-Small Cell Lung Cancer With a Triple Combination Therapy: Efficacy and Mechanisms

P1.03D.08 Padeliporphin VTP Reverts NSCLC Orthotopic Tumors in Animal Models Into Highly Responsive to aPD1 Therapy

P1.03D.09 Single Cell RNA Sequencing and Functional Monocyte Stimulation Reveals Phenotypic Predispositions to Developing Lung Cancer in Never Smokers

P1.03D.10 Uncovering the Molecular Pathways Associated with Immunotherapy-Induced Pneumonitis in Non-Small Cell Lung Cancer Patients

P1.03D.11 Association Between Plasminogen Activator Inhibitor-1 & Tolerance Against Anti-PD-1 Antibody in Non-Small Cell Lung Cancer

P1.03E.01 Effect of Gut Microbiota and Metabolites on the Efficacy of Immunotherapy Combined with Chemotherapy in Lung Squamous Cell Carcinoma Patients

P1.03F.02 Establishment of EBUS-TBNA Sample Derived Lung Cancer Organoid and Xenograft and Utility for Development of Targeted Therapy

P1.03F.03 Utility of Patient-Derived Xenograft and Xenograft-Derived Organoid Models with EGFR Mutation to Study EGFR-TKI Resistance.

P1.03G.01 Lurbinectedin Synergizes with Selinexor by Inhibiting DNA Damage Repair and Enhancing Immune Cell Infiltration in Neuroendocrine Lung Tumors

P1.03G.02 Genotyping of RB1 Status Identifies Two Distinct Subtypes in EGFR-Mutant Lung Cancers with SCLC Transformation

P1.03G.03 Role of SMARCA4, Core SWI/SNF Complex Component, in Small Cell Lung Cancer Development

P1.06A.01 Machine Learning Models Discriminate Independent Primaries with Metastatic in Non-Small-Cell Lung Cancer

P1.06A.02 Discovery of Morphomolecular Neighbourhoods in Lung Adenocarcinoma Using Self-supervised Learning

P1.06A.03 Use of Biosimulation to Predict Concomitant Chemotherapy Benefit in NSCLC Patients with EGFR Mutations Being Treated with Osimertinib

P1.06A.04 Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-Stained Histopathology Images in Lung Cancer

P1.06A.05 Assessing Pathologic Response to Neoadjuvant Chemoimmunotherapy for NSCLC: Aligning Current Protocols with Artificial Intelligence

P1.06A.06 Post-COVID-19 Tumor Microenvironment Features and AI-Based Evaluation in KRAS-Mutant NSCLC

P1.06A.07 Prognostic Gene Expression Profiling in Lung Adenocarcinoma Using Deep Learning Applied to Whole-Slide Images

P1.06B.01 NSCLC in Patients with CTD-ILD: Apobec-Related Mutagenesis, Frequent TP53 Mutations and Paucity of Targetable Alterations

P1.06B.02 A Comprehensive Analysis of FGF/FGFR Signaling Alteration in NSCLC

P1.06B.03 Genetic Profiles and Evolutionary Trajectory of Early-Stage Lung Adenocarcinoma (AAH,AIS,MIA and IA) revealed by Multiplex Sequencing

P1.06B.05 Utility of Molecular Tumor Board Driven by Precision Medicine Service and Cloud-Based Datamart for Therapy and Trial Matching

P1.06B.06 Analysis of Antibody-Drug Conjugate Target Expression Across Genomic Subsets of Non-Small Cell Lung Cancer

P1.06B.07 Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC)

P1.06B.08 The Prognostic Value of Histidine-rich Glycoprotein in Patients with Bronchial Carcinoid

P1.06B.09 Noninvasive Blood Biopsy of CRTAM-Type 3 Immune Axis Enables Dynamic Monitoring of Iraes Over the Course of Immunotherapy in Lung Cancer

P1.06B.10 Post-hoc Biomarker Analysis of Adebrelimab Plus Chemotherapy and Sequential Radiotherapy as First-Line Therapy for ES-SCLC

P1.06B.11 Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients

P1.06B.12 Racial and Socioeconomic Disparities in Molecular Diagnostics for NSCLC Patients

P1.06B.13 Blood-Based Loss of Heterozygosity in Human Leukocyte Antigen Class I Alleles Reveals Resistance to Immunotherapy in Non-Small Cell Lung Cancer

P1.06B.14 Optimal Cut-Off with NGS for Metamplification Andclinical Relevance to MET Inhibitor in Non-Small-Cell Lung Cancer

P1.06B.15 The Role and Clinical Significance of the MICOS Family in Lung Adenocarcinoma: A Focus on MIC19

P1.06B.16 HER3 Expression Across Genomic Subsets of NSCLC

P1.06B.17 Combing Circulating Tumor Cell Associated Liquid Biopsy and Radiomics to Predict the Pathology Grade of LUAD Patients

P1.06B.18 Pathologic Response Assessment of Resected NSCLC Neoadjuvant Therapy Specimens with Tumor Size Larger Than 3cm by Different Sampling Methods

P1.06B.19 Effect of Gut Microbiota and Metabolites on Malignant Pleural Effusion of Lung Adenocarcinoma

P1.06C.01 Evaluation of Small Pulmonary Pathology Specimen Management in the Province of Quebec, Canada

P1.06C.02 Description of A Single Center Thoracic Rapid Tissue Donation Program Experience

P1.06C.05 The Impact of Lymphovascular Invasion as Prognostic Factor on Long-Term Survival in More Than 3500 Resected NSCLC Patients

P1.06C.06 The Prognostic Impacts of Three Invasive Patterns in Pulmonary Peripheral Squamous Cell Carcinoma

P1.08A.01 Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Multicenter Study

P1.08B.01 Predicting Tumor Recurrence Risk in Locally Advanced NSCLC with Detectable ctDNA-Based Molecular Residual Disease: An Xgboost Model Analysis

P1.08B.02 Circulating T-Cell Immunosenescence in Patients with Unresectable Locally Advanced NSCLC: Preliminary Results of the SENLOAD Study

P1.08C.01 Targeted Therapy or Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFRm Lung Adenocarcinoma: A Study Between Four Cohorts

P1.08C.02 Revisiting the ACS 3N2 + 1N1 Mandate: Should Old Data Define Today's Standard?

P1.08C.03 Updated Event-Free Survival of Tislelizumab Plus Chemotherapy Asneoadjuvant/adjuvant Therapy for Stage IIB-IIIC NSCLC (lungmark Study)

P1.08C.04 Delineating the Prognosis Spectrum: Disentangling Primary Tumor and Lymph Node Responses in NSCLC Following Neoadjuvant Immunotherapy

P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study

P1.08D.01 The Efficacy of Durvalumab after Concurrent Chemoradiotherapy for EGFR-Mutated Stage III Non-Small Cell Lung Cancer (NEJ063)

P1.08D.02 Survival after Salvage Treatment Following Durvalumab Consolidation in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)

P1.08D.03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)

P1.08D.04 The Clinical Outcomes of Contralateral Esophagus Sparing IMRT in Concurrent Chemoradiotherapy for Stage III Lung Cancer

P1.09A.01 The Effectiveness of Split-course Stereotactic Body Radiation Therapy in Treating Large Thoracic Cancer

P1.09A.02 Pathologic Tumor Positivity vs Only Necrosis in Clinically Suspected Recurrent Brain Metastasis Post-Radiation

P1.09A.03 Concurrent Combination of EGFR-TKIs and Thoracic Radiation Therapy for Metastatic Non Small Cell Lung Cancer Patients

P1.09B.02 Double Lung Transplantation in Patients with Metastatic Lung-limited Non-Small Cell Lung Carcinoma (NSCLC).

P1.09B.03 Ex-Situ Lung Transplantation without Heparinization: A Novel Surgical Approach for Locally Advanced and Central Lung Carcinoma

P1.09B.04 Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data

P1.09B.05 Improved Survival of Primary Tumor Resectionfor Metastatic Non Small Cell Lung Cancer:a Propensity Score-matched Analysis

P1.09C.01 A Multicenter, Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients

P1.09C.02 SiCARIO: A Phase I/II Study of Split Course Adaptive Radioimmunotherapy for the Treatment of Oligometastatic Non-Small Cell Lung Cancer

P1.09C.03 IMMUNOResist: Defining the Immunophenotype of Immunotherapy Resistance with PD-L1 and CD8 Novel Tracer PET

P1.12A.01 Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm

P1.12A.02 Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with NSCLC Harboring EGFR Exon 19 Insertions: A Report from the LC-SCRUM-Asia

P1.12A.03 Outcome and Transcriptomic Features of Dual EGFR and MET Blockade in NSCLC

P1.12A.04 Socioeconomic Disparities and Overall Survival Differences Among Ethnic-Minority Patients with EGFR-Mutated NSCLC Treated with Osimertinib

P1.12A.05 Aumolertinib in Treatment-Naïve EGFR-Mutant NSCLC Patients with Brain Metastases:Efficacy and Safety Data from the ARTISTRY

P1.12A.06 A Phase II 80 Mg Osimertinib in Patients with Leptomeningeal Metastases Associated with EGFR Mutation-Positive NSCLC (BLOSSOM)

P1.12A.07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation.

P1.12A.09 A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

P1.12A.10 Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFR-Mutated NSCLC

P1.12A.11 Analysis of Uncommon EGFR Exon 19 Alterations Identified by Liquid Biopsy in Advanced Non-Small Cell Lung Cancer (NSCLC)

P1.12A.12 Liquid Biopsy Based Risk Stratification and Intensification of Treatment in EGFR Mutant Advanced NSCLC (L-BRITE) Preliminary Analysis

P1.12A.13 When Targeted Therapy Targets the Heart: Osimertinib-related Cardiotoxicity in EGFR Mutated Non-Small Cell Lung Cancer

P1.12B.01 Intracranial Efficacy of Lorlatinib via RANO-BM in ALK-Fusion NSCLC with CNS Metastases: A Retrospective, Multicenter Study

P1.12B.02 Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer

P1.12B.03 Real-World Outcomes of 2L ALK TKIs Following 1L Brigatinib for Patients with ALK+ NSCLC from the ALTA-1L Trial

P1.12B.04 Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes

P1.12B.05 Patient and Oncologist Preferences for ALK+ Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

P1.12B.07 Iruplinalkib in Patients with ALK-Positive Crizotinib-Resistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial

P1.12B.08 Thrombotic Events at Diagnosis are Associated with Poorer First Line TKI Outcomes Among Metastatic ALK and ROS1 NSCLC Patients

P1.12B.09 Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials

P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC

P1.12B.11 ALK Positive Lifestudy

P1.13A.01 DeLLphi-306 Trial: A Phase 3 Study of Tarlatamab after Concurrent Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer

P1.13A.02 Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial

P1.13A.03 MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC

P1.13A.05 Preliminary Results of A Phase II Study of Camrelizumab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for LD-SCLC

P1.13A.06 Outcomes in LS SCLC Patients with Severe Acute Esophagitis During Chemotherapy and Concurrent Twice-Daily Thoracic Radiotherapy

P1.13A.07 Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study

P1.13A.08 Biomarker Analysis of Camrelizumab Plus Nab-paclitaxel and Carboplatin as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer

P1.13A.09 RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer

P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study

P1.13A.11 Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study

P1.13A.12 Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients

P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study

P1.13B.01 Lurbinectedin vs. Platinum Rechallenge in Extensive Stage Small Cell Lung Cancer after Platinum Doublet, A Multicenter Retrospective Study

P1.13B.02 Radiation Necrosis in Small Cell Lung Cancer Patients

P2.04A.01 FIRSTLUNG (L301): Cluster Randomized Trial Evaluating the Clinical Utility of DELFI's Blood-Based Lung Cancer Screening Test

P2.04A.02 Using an AI Transformer Model to Identify Incidental Pulmonary Nodules (IPN) For Lung Cancer Early Detection

P2.04A.03 Enhancing Participation in Flemish Lung Cancer Screening: Strategies for Engaging the Hard-To-Reach

P2.04A.04 The Lung Health Check Pilot: Ireland's Flagship Lung Cancer Screening Trial

P2.04A.05 Providing Tobacco Treatment to Patients Undergoing Lung Cancer Screening at a Large U.S. Health System: A Randomized Trial

P2.04A.06 A Multilevel Approach to Address Disparities in Lung Cancer Screening: The PREP Trial

P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)

P2.04A.08 Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

P2.04B.01 Argentine Lung Cancer Screening Programes Collaborative Registry: The LuCaS.Ar Project

P2.04B.02 Eight Year Outcomes of a Multidisciplinary Lung Cancer Screening Program at a Large Community Centre in Canada

P2.04B.03 Low Cost Low Dose CT Scan for Lung Cancer Screening - Seven Year Experience at a Sub-urban Community Hospital.

P2.04B.04 Harnessing EHR/IT to Accelerate Lung Cancer Screening - An American Cancer Society National Lung Cancer Roundtable Initiative

P2.04B.05 Engaging Culturally and Linguistically Diverse Communities to Prepare for Lung Cancer Screening Implementation in Australia.

P2.04B.06 Lung Cancer Screening Program in Serbia: A 3-year- Results and Challenges

P2.04B.07 Impact of Primary Care Initiated Lung Cancer Screening Program: The VANCHCS Experience

P2.04B.08 Terminology in Lung Cancer Screening and Early Detection - IASLC Early Detection and Screening Committee Recommendations

P2.04B.09 A Qualitative Evaluation of the Critical Role of Lung Cancer Screening Program Navigators

P2.04B.10 Leveraging High Mammography Screening Prevalence to Increase Lung Cancer Screening Among Women - A Geospatial Perspective

P2.04B.11 Factors Associated with Early-Stage Lung Cancer Diagnosis (ESLCD) In Brazil - 2013 - 2019: A Multivariable Analysis.

P2.04B.12 Respiratory Function as a Prognostic Factor for Lung Cancer in Screening and General Populations

P2.04B.13 Time to Benefit: A Systematic Review and Meta-Analysis of Lung Cancer Screening Trials

P2.04B.14 Barriers to Maximal Screening Impact in Persons Diagnosed with Lung Cancer in a Prospective Cohort.

P2.04B.15 Co-Design of Decision Support Tools for Lung Cancer Screening in Australia

P2.04B.16 Real-World First Round Results from a Charity Lung Cancer Screening Program in East Asia

P2.05A.01 Clinical Presentation, Outcomes, and Anticoagulant Strategies in Patients with Lung Cancer-Associated Isolated Distal Deep Vein Thrombosis

P2.05A.02 Incidence of Pneumonitis in Asian Patients with Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis

P2.05A.03 Regional Disparities in Distant Metastatic Lung Cancer Patients and Overall Survival in Norway. A Nationwide Population Study

P2.05A.04 Does the Treating Physician's Specialty-Oncology or Pulmonology-Affect Clinical Outcomes and Survival in Lung Cancer Patients?

P2.05B.01 How Reliable Is PET/CT in T1A and T1B Non-Small Cell Lung Cancer for Mediastinal Staging?

P2.05B.02 Automated Extraction of Key Entities from Thorax CT Reports Using NER with Prompt Engineering

P2.05B.03 A Novel Lung Nodule Localize Method: Topographic Map Dyeing Model for Target Vessel Watershed Boundary

P2.05B.04 Development of a CT Image-Based Virtual Atelectasis Simulation Model and Noninvasive Lung Nodule Localization System

P2.05C.01 Pathologic Nodal Staging Reporting Quality: A Multi-Center Assessment of NSCLC Trends Over Time & Key Reporting Parameters

P2.05C.02 Does the Proposed 9th TNM Offer Improved Prognostic Accuracy after Lung Carcinoma Resection? Preliminary Analysis Results

P2.07A.01 Clinicopathological vs. Molecular Models in Predicting Adjuvant EGFR-TKI Benefit in Stage I NSCLC

P2.07A.02 The Effect of EGFR Mutation on Adjuvant Tegafur/Uracil for Patients with Non-Lymph Node Metastatic NSCLC (> 2 Cm)

P2.07A.03 Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study

P2.07A.04 Clinical Relevance of PD-L1 Expression Levels in Surgically Resected EGFR-Mutant Lung Adenocarcinoma Patients (CReGYT-01 Study)

P2.07B.01 Single Versus Multiple Segmentectomies: A Comparison of Short- And Long-Term Outcomes

P2.07B.02 Is Wedge Resection Really Enough for the Treatment of Patient with Stage I Non-Small Cell Lung Cancer? A SEER Database Analysis.

P2.07B.03 Simultaneous Bilateral Video-Assisted Thoracic Surgery Is Safe and Feasible for Multiple Primary Lung Cancers

P2.07B.04 Comparative Effectiveness of Sub-Lobar Resection vs Lobectomy for Medically Operable Stage I NSCLC: A VACCR Analysis

P2.07B.05 Prospective Comparative Study of Postoperative Respiratory Function after Lobectomy Versus Segmentectomy

P2.07B.06 Segmentectomy for cIA1-2 Lung Cancer in the Lower Lobe with Solid-Predominant Opacity: Impact on Recurrence and Survival Rates

P2.07B.07 Multi-Institutional Retrospective Analysis of Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Larger Than 3 cm in Diameter

P2.07B.08 Outcome Comparison Between Left Upper Lung Lobectomy and Split Lobe Segmentectomy for Clinical Stage I Lung Cancer

P2.07B.09 Real-World Validation for Impact of Sublobar Resection Over Lobectomy on Lung Cancer Survival and Frailty Using SEER-Medicare

P2.07B.10 Should Lymph Node Dissection Be Routinely Undertaken for Patients with Small-Sized Solid-Dominant Non-Small-Cell Lung Cancer?

P2.07B.11 Delays to Lung Cancer Surgery by Biopsy Technique

P2.07C.01 LCMC3: Clinical Utility of Suvmax on Preoperative 18F-FDG PET-CT in Resectable NSCLC Treated with Neoadjuvant Atezolizumab

P2.07C.02 Prognostic Impact of Adjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer Following Neoadjuvant Immunotherapy

P2.07C.03 Limited Efficacy of Immunochemotherapy in Pulmonary Invasive Mucinous Adenocarcinoma and Mucoepidermoid Carcinoma as Neoadjuvant Setting

P2.07C.04 Surgical Complexity of Anatomical Lung Resections after Induction Immunotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

P2.07C.05 Perioperative (Neoadjuvant Plus Adjuvant) Immunotherapies for Resectable NSCLC:A Systematic Review and Meta-Analysis of Phase 3 Trials

P2.10A.01 Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)

P2.10A.03 RESOLUTION: Phase II Study of Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in Patients with HER2 Alteration Advanced NSCLC

P2.10A.04 Valemetostat and Datopotamab Deruxtecan in Previously Treated, Advanced, Unresectable, or Metastatic Non-squamous NSCLC

P2.10A.05 Ipat-Lung: A Multi-Center Phase 2 Study of Ipatasertib Plus Docetaxel in NSCLC Patients who Have Failed or Are Intolerant to 1st Line Immunotherapy

P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations

P2.10A.07 Trofuse-009: Phase 3 Study of Sac-TMT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC

P2.10B.01 Exploratory Analyses of Tusamitamab Ravtansine vs Docetaxel in Previously Treated Non-squamous NSCLC Patients: CARMEN-LC03

P2.10B.02 Cutoff Determination for C-met Protein Overexpression by VENTANA MET (SP44) IHC to Determine Teliso-v Eligibility in NSCLC

P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study

P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

P2.10B.05 Renal Toxicity in Patients with Non-Small Cell Lung Cancer Receiving Maintenance Therapy with Pemetrexed and Pembrolizuma

P2.10B.06 Improvements in Survival Outcomes of Large Cell Carcinoma Over Past Two Decades (2000-2020)

P2.10B.07 Chemotherapy in Combination with Anti-PD1 in PD-L1-Negative Non-Small Cell Lung Cancer Patients: A Single-Center Experience

P2.10B.08 Opportunities for ADC Development in 2L NSCLC Leveraging Predictive Biomarkers

P2.11A.01 Racial/ethnic Differences in Real-World Adverse Events and Survival Among Patients on Immunotherapy for Advanced NSCLC

P2.11A.02 Proteomics-Based Target Identification for Optimizing Bispecific Antibody Use in NSCLC

P2.11A.03 Association of LIPI with Patterns of Response, Resistance, and Survival in Patients with Metastatic NSCLC Treated with PD(L)-1 Blockade

P2.11A.04 Exhaled Breath Biomarkers of Response to Immunotherapy in Advanced Non-Small Lung Cancer

P2.11A.05 The Impact of Tumor Molecular Features and Smoking History on Survival with Chemo-Immunotherapy in EGFR-Mutant NSCLC

P2.11A.06 Tumor-Informed ctDNA Status Guiding 1st-line Immuno-Chemotherapy in Advanced NSCLC: CHOICE-01 Retrospective Analysis

P2.11A.07 Selected Shared Neoantigens for Personalized Tumor Neoantigen Peptide Vaccine in the Treatment of Advanced Tumors

P2.11A.08 Molecular and Immunological Features Associated with Long-Term Benefit in Metastatic NSCLC Patients Undergoing Immune Checkpoint Blockade

P2.11A.09 Survival Outcomes of Lung Adenocarcinoma with Intestinal Differentiation in the Era of Immunotherapy

P2.11A.10 Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases

P2.11A.11 Impact of Proton Pump Inhibitor Use on Faecal Microbiome in Patients with NSCLC Treated with Immune Checkpoint Inhibitor

P2.11A.12 Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer

P2.11A.13 Cytokine Release Syndrome from Dual Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: FAERS Analysis

P2.11A.14 Research of the Predictive Role of Immune Cells and Intestinal Flora on Immune-related Adverse Event in Lung Cancer

P2.11A.15 Gut Metatranscriptomics Predict Survival in Anti-PD Immunotherapy Treated Advanced-Stage Non-Small Cell Lung Cancer

P2.11A.16 Categorizing Steroid-Response Types in Checkpoint Inhibitor-Related Pneumonitis

P2.11A.17 Impact of Mutation Class and Smoking Status in BRAF-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated with Immune Checkpoint Inhibitors (ICI)

P2.11A.20 Metformin Enhances Immune Checkpoint Inhibitor Response in Overweight Lung Cancer Patients: A Retrospective Cohort Study

P2.11A.21 CCL4 Attenuated the Efficacy of Immunotherapy via Regulating the Phenotype and Function of Treg in EGFR-TKI Resistant NSCLC

P2.11A.22 Higher Blood TMB/Tissue TMB Ratio as an Inferior Prognostic Biomarker for Survival in Advanced Stage NSCLC

P2.11A.23 Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study

P2.11A.24 Characterization of Circulating Tumor-Associated and Immune Cells in Advanced-Stage NSCLC

P2.11A.25 Clinicogenomic Profile of Different Resistance Patterns to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab

P2.11A.27 Generalizability of Radiomics Based Progression Risk Models in Immunotherapy Treated Mnsclc Subjects

P2.11B.01 Deciphering Immunotherapy Resistance Mechanisms in Metastatic NSCLC, Insights from Plasma Proteomics Analysis

P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer

P2.11B.03 Circulating Hallmarks of Hyperprogression in NSCLC upon 1st Line PD-(L)1 Inhibitors Alone or in Combination with Chemotherapy

P2.11B.04 Chemotherapy Increases Acquired Resistance to Immunotherapy in NSCLC: A Metanalysis of Aggregate and Individual Patient Data

P2.11B.05 Effect of Dysbiosis-Inducing Drugs on the Response to Immune Checkpoint Inhibitors in Patients with NSCLC

P2.11B.06 BIRC5 Expression Correlated with Immunosuppressive Phenotype and Predicted Inferior Response to Immunotherapy in LUAD

P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer

P2.11C.02 Incidence of Hematological Toxicity with Use of Immunotherapy and Chemotherapy in Advanced NSCLC: A Network Meta Analysis

P2.11C.03 Immune-Related Adverse Events are Associated with Survival in Chinese Lung Cancer Patients Treated With Immunotherapy

P2.11C.04 Enhancing Multidisciplinary Clinicians' Ability in Identifying and Managing irAEs in the Emergency Setting Through Online CME

P2.11C.05 Correlation Between Gut Microbiome and Immune-Related Adverse Reactions for Lung Cancer

P2.14A.01 Clinicopathological Characteristics and Treatment Outcomes of Patients with Advanced SMARCA4-Deficient Non-Small Cell Lung Cancer

P2.14A.02 Assessment of Immunohistochemical Panel Utilization in Thymic Carcinoma Diagnosis: Real World Experience Insights

P2.14A.03 Prediction of Post-Surgical Recurrence of Thymic Epithelial Tumours Using Clinicopathological Parameters Incorporating TNM9 Classification

P2.14A.05 Validity of Simple Thymomectomy for Clinical Stage I Thymoma without Myasthenia Gravis: A Propensity Score-Matched Analysis

P2.14A.07 Learning Curve Analysis of Near-Infrared Fluorescence-Guided Robotic-Assisted Minimally Invasive Esophagectomy with Indocyanine Green Dye

P2.14A.08 Tyrosine Kinase Inhibitors (Alone or in Combination) for the Management of Advanced Thymic Epithelial Tumors (TETs) Among Hispanics

P2.14A.09 Adaptive Reprogramming of Arginine Biosynthesis is an Attractive Target for Modulating the Response to WEE1 Inhibition in Pleural Mesothelioma

P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma

P2.14A.11 Real-World Immunotherapy Use in Pleural Mesothelioma: Insights & Immunological Landscape

P2.14A.12 Unveiling COL17A1 as a Novel Cell Surface Target in Thymic Epithelial Tumors: A Target Discovery Pipeline Approach

P2.14A.13 Discovery and Clinical Application of Potential Prognostic Genes for Clinical Outcome in Malignant Pleural Mesothelioma

P2.14A.14 A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

P2.14B.01 [DREAM] Double Lung Transplant Registry Aimed for Lung-limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers

P2.14B.02 Application of Chemokine Receptor 4 Targeted 68Ga Pentixafor in Evaluation of Thymic Epithelial Tumors (TETs): A Prospective Study

P2.14B.03 A Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients with Advanced Thymoma and Thymic Carcinoma

P2.14B.05 eVOLVE-Meso: A Global Phase 3 Study of First-Line Volrustomig Plus Chemotherapy in Unresectable Pleural Mesothelioma

P2.16A.01 Actionable Alterations Identification in NSCLC by Comprehensive Genomic Profiling for Clinical Trial Enrollment: EPROPA

P2.16A.02 Improving Patients' Awareness of Biomarker Test Timing and Purpose with 4R Oncology Intervention

P2.16B.01 Attributes that Impact Patient and Physician Preferences for Maintenance Treatment in Advanced/metastatic NSCLC

P2.16C.01 Awareness, Stigma, and Fatalism Towards Cancer Clinical Trials Among Black Individuals Diagnosed with Lung Cancer

P2.16C.02 Development of a Framework to Address Lung Cancer Health Disparities: One Organization's Experience

P2.16D.01 Changes in Students' Perceptions of Cancer Through Cancer Education and Lectures by External Instructors with Cancer Experience

P2.16E.01 Lung Cancer Patients' Support Preferences: Insights from a Global Patient Experience Survey

P2.16E.02 Emotional Support Resource Access and Utilization Among People with Lung Cancer

P2.16F.01 Patient-Led Oncogene-Driven Lung Cancer Translational Research to Expedite Therapeutic Development

P2.16F.02 LIFE Project: Lung Cancer Patients' Involvement in Research Fostering Their Empowerment

P2.16F.03 Development of a Patient-Friendly Lung Cancer Lexicon

P2.16G.01 Annual Lung Cancer Screening Day in the United States- Year Two

P2.16G.02 "It's Like A Donut!"- Veteran Perspectives of Lung Cancer Screening with Low Dose CT

P2.17A.01 Treatment Outcomes after Access to Broad Molecular Tests, Targeted Agents and Immunotherapy in NSCLC Patients from Brazil

P2.17A.02 Cost-Efficiency Modeling of Conversion to Biosimilar Bevacizumab-bvzr in Metastatic Non-Small Cell Lung Cancer in Medicare

P2.17A.03 Preoperative Anxiety in Patients Undergoing Video-Assisted Thoracoscopic Surgery: Predictive Factors and Specific Concerns and Fears

P2.17A.04 Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients

P2.17A.05 Racial and Gender Disparities in Immune-Related Adverse Effects: A Nationwide Inpatient Sample Database Analysis

P2.17A.06 Impact of COVID-19 Diagnosis and Treatment for Lung Cancer in the US National Cancer Database (NCDB) from 2014 To 2021

P2.17A.07 Impact of Preoperative Anxiety on Postoperative Outcomes in Patients Undergoing Minimally Invasive Thoracoscopic Surgery

P2.17A.08 Trends in Pulmonary Embolism Outcomes Among Lung Cancer Patients: A Nationwide Analysis Across a Decade

P2.17A.09 Real-World Study of the Efficacy and Safety Analysis of Immunotherapy in Advanced Lung Cancer Under Internet-Based Full-course Management

P2.17A.10 Major Cardiovascular and Cerebrovascular Events in Lung Cancer - A Nationwide Inpatient Sample Database Analysis.

P2.17B.01 The Construction and Application of a Novel Precise Health Management Model for Lung Nodule Population

P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols

P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits

P3.01D.01 Racial Disparities Among Patients Diagnosed with Lung Cancer at a Young Age

P3.01D.02 Lung Cancer Incidence Trends by Histology and Sociodemographic Characteristics in the US from 2000-2019

P3.01D.03 Evaluating Lung Cancer Disparities Among Transgender Populations: A Retrospective Cohort Analysis

P3.01D.04 Disparities in Lung Cancer Risk Assessment for People Living with HIV

P3.01D.05 Gender Differences in Lung Cancer Incidence Among Patients Who Never Smoked Cigarettes: A Systematic Literature Review

P3.01E.01 Real-World Analysis of GLP-1 Receptor Agonists and Lung Cancer Risk in Treatment-Naïve Type 2 Diabetes: Potential Impact of Obesity and Gender

P3.01E.02 Association Between Composite Dietary Antioxidant Index and Lung Cancer Risk in Former Smokers: A Large Prospective Cohort Study in UK Biobank

P3.01F.01 Evaluating the Relationship Between Veteran Toxic Exposure Status and Lung Cancer Prevalence

P3.01F.02 Retrospective Characterization of Patients with Primary Lung Cancer Related to World Trade Center Disaster Exposure

P3.02F.01 CD47 Promotes Migration and Metastasis in Non-Small Cell Lung Cancer

P3.02F.04 Investigating the Role of Lactate Import and Metabolism in Non-Small Cell Lung Cancer

P3.02F.05 A Genetic Engineering Approach to Interrogate Myosin 10 As a Driver of Non-Small Cell Lung Cancer Metastasis

P3.02F.06 Multi-Omics Reveals Effects of Gut Microbiome on Tumor Immune and Metabolism in Mouse Lewis Lung Carcinoma Model

P3.02G.01 Therapeutic Targeting of Lung Cancer-Associated Fibroblasts Mitigates Mediastinal Lymphatic Dissemination in Non-Small Cell Lung Cancer

P3.02G.03 High-Dose Ascorbic Acid Sensitizes Immunotherapy in LKB1-Deficient Lung Cancer by Promoting Tumor Cell Pyroptosis

P3.02G.04 JP11646-mediated PIM2 Inhibition Has Potent Antitumor Effects in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung

P3.03H.01 Tumour Educated Platelets Display A Distinct RNA Content Profile Across Metastatic Patterns in NSCLC.

P3.03H.02 PMS2 Amplification Contributes Brain Metastasis from Lung Cancer

P3.03H.03 Feasibility of Metastatic Lymph Node-informed ctDNA Analysis in Surgically Resected NSCLC Patients

P3.03H.04 Molecular and Clonal Evolution of Primary Lesions vs Brain Metastasis and Progressive Disease of EGFR Mutated Patients

P3.03H.05 AKAP12 Deficiency Leads to Blood-Brain Barrier Disruption and Serves as a Crucial Diagnostic Marker for Brain Metastasis in Lung Adenocarcinoma

P3.03I.01 Targeting RLIP76 with a Novel Small Molecule for Lung Cancer Therapy

P3.03I.02 Co-Inhibition of MEK/RTK Pathways Induces High Therapeutic Efficacy in Pan-KRAS-Mutant Non-Small Cell Lung Cancer

P3.03I.05 DSTYK Inhibition as a Novel Strategy for Taxane-Based Chemotherapy Sensitation in Early and Advanced Lung Cancer

P3.03I.06 Neoadjuvant Gefitinib in EGFR Mutated NSCLC (a Phase 2 Window-Of-Opportunity Study): Deep Genomic and Transcriptomic Analysis

P3.03I.08 Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy

P3.03I.09 Augmenting Post-Surgical Tumor Immune Response and Recurrence Prevention via Nanoparticle-Assisted Targeted Drug Delivery

P3.03I.11 The ATXN3-USP25-TRMT1 Axis Regulates tRNAm2,2G Modification and Promotes Osimertinib Resistance in Lung Cancer

P3.03I.12 Modulation of EMT Increases the Activity of Lurbinectedin in Small Cell Lung Cancer

P3.03I.13 High EGFR Expression Confers Acquired Resistance to Adagrasib - In Vitro Study Using KRASg12C Mutated Lung Cancer Cells

P3.03I.14 Osalmid Inhibits the Progression of Lung Adenocarcinoma and Sensitizes It to EGFR-TKIs: A Preclinical and Translational Study

P3.03I.15 The Mechanisms and Impact of EGFR TKIs in Modulating Blood Immune Cells in Patients with Oncogene-Driven NSCLC

P3.03I.16 Treatment Outcomes in Patients who Received Bevacizumab Therapy for Radiation Induced Brain Necrosis

P3.03I.17 Exploring Autophagy Flux-Related Molecules to Overcome in Acquired Resistance to EGFR TKIs in NSCLC Patients Harboring EGFR Mutations

P3.03I.18 Optimizing Delivery of Anti-Cancer Therapeutics in Lung Adenocarcinoma Using Ultrasound-Induced Cavitation of Microbubbles

P3.03I.19 The International Pregnancy and Lung Cancer Registry at Dana-Farber Cancer Institute

P3.03J.01 Genomic and Spatial Characterization of Neoadjuvant Efficacy Differences in Non-Small Cell Lung Cancer

P3.03J.03 Genetic Signature Derived from Single-Cell Defined Microenvironment Remodeling Correlate with Efficacy of Neoadjuvant Immunotherapy in LUSC

P3.03J.04 Single-Cell Landscape of Senescent Cells in the Lung Cancer Microenvironment Unveils Pivotal Roles of Senescent Cancer Cells

P3.03J.05 Enhancement of Chemotherapy and Immunotherapy in LUSC Animal Models Through Tumor Microenvironment Remodeling by Losartan

P3.06D.01 Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Treatment-Naive Patients with Advanced Lung Squamous Cancer

P3.06D.03 Prognostic and Predictive ctDNA Signature for Patients on Targeted Therapy for Metastatic NSCLC: A Pathway-based Approach

P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

P3.06D.05 Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA

P3.06D.06 Incremental Value of Liquid Biopsy in the Initial Evaluation of Non-Small Cell Lung Cancer Patients Undergoing Tissue Based Molecular Testing

P3.06D.07 Liquid Biopsy: Exploration of its Added Value in a Daily Practice

P3.06D.09 Reciprocal DNA Fusions and their Association with DNA Damage Response Genes in Patients with NSCLC Through cfDNA NGS

P3.06D.10 Concordance of Liquid Biopsy and Tissue Biopsy for the Detection of EGFR Mutation in Stage III NSCLC in the United States

P3.06D.13 Patterns of Tissue NGS Alterations are Associated with ctDNA Shedding in Non Small Cell Lung Cancer Tumors Harboring EGFR Mutations

P3.06D.14 Liquid Biopsy-Based Single T-Cell Dynamic Polyfunctionality Profiling as a NSCLC Immunotherapy Biomarker

P3.06E.01 Evaluation of the Immune Landscape of Patients with Adenosquamous NSCLC (LUAS)

P3.06E.02 Serum NY-ESO-1 And XAGE1 Antibodies Are Diagnostic and Cancer-Specific Immunomonitoring Markers in NSCLC

P3.06E.03 Anlotinib Mediated Inflammation Response Through NFKB/TNFRSF11A Cascade in Lung Cancer

P3.06E.04 Genetic and Immunological Backgrounds in Advanced NSCLC Patients Treated with Immunotherapy - NGS and Flow Cytometry Analysis

P3.06E.06 Angiogenesis and Immune-Related Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

P3.06F.01 Proteomic Profiling Reveals Distinct Biological Characteristics of EGFR L858R Mutation and a Prognostic Model in Lung Adenocarcinoma

P3.06F.02 Role of GOLT1B and PTGES3 In Suppressing Lung Adenocarcinoma Progression

P3.06F.03 Unbiased Proteomics and Multi-Omics Discovery of a Peripheral Blood-Based Classifier for Early Lung Cancer Detection

P3.06F.04 Multi-Omics Analysis of SMARCA4-Deficient Tumors

P3.06F.05 Spatial Profiling of the Tumor Microenvironment of SMARCA4-Mutant NSCLCs Using Whole-Slide Multiplex Fluorescence Imaging

P3.06F.06 Spatial Transcriptomic Profiling Reveals Molecular Patterns Associated with Poor Prognosis in ALK-Rearranged NSCLC Patients

P3.06F.07 Effect of Neoadjuvant Chemotherapy on the Spatial Landscape of Regulatory T Cells in Non-Small Cell Lung Cancer Patients

P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival

P3.08E.02 An Artificial Intelligence Driven Approach to Predict Pathological Response to Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer

P3.08E.03 Dynamics of Peripheral Blood Inflammatory Index Predict Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials

P3.08E.05 Radiological, Metabolic and Prognostic Features of Primary Tumor and Metastatic Lymph Node in Lung Cancer with Neoadjuvant Chemoimmunotherapy

P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)

P3.08F.03 NRG LU008: Phase III Randomized Trial of Primary Tumor SBRT Followed by Concurrent Mediastinal Chemoradiation for LA-NSCLC

P3.08F.04 Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer: An Update on the VIGILANCE Study

P3.08F.06 PLATINUM Trial: Preliminary Analysis of Lazertinib Therapy in Locally Advanced, Unresectable, EGFR Mutation(+) NSCLC Following CCRT

P3.08F.07 Efficacy and Safety of Envafolimab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB NSCLC

P3.08F.08 NEOLA: Phase II Study of Osimertinib Treatment Before and after Chemoradiotherapy in Unresectable Stage III EGFRm NSCLC

P3.12C.01 BRAF Mutation Diversity and Impact on Clinical Outcomes in Non-Small Cell Lung Cancer

P3.12C.02 MET Fusions in NSCLC: Prevalence, Oncogenicity, and Resistance Mechanism

P3.12C.03 Efficacy and Safety of Brigimadlin, a MDM2-p53 Antagonist, in Patients with Advanced Lung Adenocarcinoma

P3.12C.04 Seribantumab Results in Robust and Durable Responses in NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multi-Center Case Series

P3.12C.05 Thromboembolic Events in Patients with Oncogene-Addicted Advanced NSCLC

P3.12C.06 Clinical Characteristics and Outcomes in Patients with Leptomeningeal Disease (LMD) from Non-Small Cell Lung Cancer

P3.12C.07 Breaking New Ground: Selecting the Best Treatment for Non-Small Cell Lung Cancer According to Mutational Status

P3.12C.08 Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study

P3.12D.01 A Phase Ib Study of Osimertinib and Tegavivint as First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

P3.12D.02 Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)

P3.12D.03 A Study to Investigate Safety, PK, And Anti-Tumor Activity of TRX-221 In EGFR Mutant NSCLC: TRX-221-001 In Progress

P3.12D.04 Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

P3.12D.05 Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups

P3.12D.06 Beamion LUNG-1 And LUNG-2: The Zongertinib Clinical Program in Patients with Non-Small Cell Lung Cancer and HER2 Mutations

P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

P3.12D.08 DCC-3116 In Combination with Sotorasib in Advanced or Metastatic KRASG12C-Mutant Cancers: First-in-human Phase 1/2 Study

P3.12D.09 Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous Non-Small Cell Lung Cancer

P3.12D.11 Phase 1/2, Dose-expansion Study of AMG 193, an MTA-cooperative PRMT5 Inhibitor, In MTAP-deleted NSCLC

P3.12E.03 Anti-Tumor Efficacy of HRS-4642 and its Potential Combination with Proteasome Inhibition in KRAS G12D-Mutant Cancer

P3.12E.04 Long-Term Outcomes with Sotorasib in KRAS G12c-Mutated Advanced NSCLC from the Global Expanded Access Program (EAP) Study-436

P3.12E.05 Real-World Comparative Effectiveness of Sotorasib vs Docetaxel as 2L/2L+ Treatment of KRAS G12c-Mutated Advanced NSCLC

P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving Immunotherapy

P3.13C.03 Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC

P3.13C.04 Assessing ctDNA using a Methylation-informed Molecular Response Algorithm in Extensive-Stage Small Cell Lung Cancer Patients

P3.13C.05 Relationship Between Tumor Volume and Clinical Outcomes in Relapsed SCLC

P3.13C.06 Artificial Intelligence Meets SCLC - Integrating Clinicopathological and Whole-Slide Image Data for Prognostic Prediction in SCLC.

P3.13C.08 Optimal Treatment Strategies for Older Adults with Clinical Stage IA Small Cell Lung Cancer

P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study

P3.13D.02 DLL3 Expression in Early-Stage SCLC: Comparative Analysis of IHC and mRNA ISH in Tumor and Lymph Nodes

P3.13D.03 Inhibition of LSD1 Prevented Tumor Progression and Recurrence to Radioimmunotherapy in Small Cell Lung Cancer

P3.13D.04 Extrachromosomal MYC-Paralogs Amplification Defines Immunosuppressive Microenvironment with Metastatic Potential in Small Cell Lung Cancer

P3.13D.06 Distinct Single-Cell Transcriptomic Characteristics and Responses to the Front-Line Therapy in Patients with Central or Peripheral ES-SCLC

P3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer

P3.13D.10 Clinical Outcomes of Transformed Small-Cell Lung Cancer Versus Extensive Primary Small-Cell Lung Cancer

P3.13D.11 SEZ6 Expression in Neuroendocrine Tumors

P3.13E.01 Is Systematic Lymphadenectomy Pivotal for Bronchial Carcinoid Surgical Treatment? A TNM 9th Classification Validation Pilot Study

P3.13E.02 Adjuvant Chemotherapy in cT1N0M0 Large-Cell Neuroendocrine Cancer with or without Pathological Upstaging

P4.04C.01 Incidental Pulmonary Nodule Management Using Computer Assisted Detection and Patient Tracking: PINPOINT Project, Pilot Data

P4.04C.02 Discrimination of Lung Cancer and Benign Lung Diseases Using BALF Exosomal DNA Methylation Profile

P4.04C.03 Nodule Type Classification for Lung Cancer Screening with CT

P4.04C.04 Epidemiological Characteristics of Incidental Pulmonary Nodules and in China: A Prospective Multicenter Trial of 10,560 Cases

P4.04C.05 AI-Assisted CXR Analysis in the Detection of Lung Nodules and Incidental Lung Cancers

P4.04C.06 DNA Methylation Analysis in Plasma for Early Diagnosis Inlung Adenocarcinoma

P4.04C.07 Improving the Efficiency of Lung Cancer Screening Through a Blood-based Lung Cancer Screening Test Prior to Low-Dose CT

P4.04C.08 Sensitivity of Artificial Intelligence in Low-dose Computed Tomography Screening for Lung Cancer

P4.04C.09 Exhaled VOC Detection in Lung Cancer Screening: A Comprehensive Meta-Analysis

P4.04C.10 Validation of LungFlag™ Prediction Model Using Electronic Medical Records (EMR) On Taiwan Data

P4.04C.11 Pixel-Wise Pulmonary Nodule Growth Prediction on Low-Dose Computed Tomography with 3D-ConvLSTM Deep Neural Network

P4.04D.01 Gender Disparities in Lung Cancer Screening: A Systematic Literature Review

P4.04D.02 Lung Cancer in Never Smokers and Individuals with a Family History of Lung Cancer: Missed Opportunities for Screening

P4.04D.03 Lung Cancer in Those Who Never Smoked Study (luCNeSS) - Preliminary Analysis

P4.04D.04 Efficiency of the Annual CT Screening Interval for Those at a Lower Risk of Lung Cancer - A CISNET Comparative Modelling Study

P4.04D.05 Family History is an Independent Predictor of Lung Cancer Detection in Women in a Predominantly Caucasian Screening Cohort

P4.04D.07 Lung Cancer Biomarkers in Nonsmokers: Diagnostic and Prognostic Use of Liquid Biopsy for Metabolites Found in the Urine

P4.04D.08 Natural History Model for Second Primary Lung Cancer Among Lung Cancer Survivors: Utilizing the U.S. SEER Cancer Registries

P4.04D.09 Assessing the Risk of Second Primary Lung Cancer in Women after Previous Breast Cancer

P4.04D.10 Risk-Based LDCT Screening for Non-smokers in Taoyuan, Taiwan

P4.07D.01 Neoadjuvant Osimertinib Followed by Radiation And/or Surgery in Stage III EGFR-Mutant NSCLC: An Open-Label, Single-Arm, Phase 2 Study

P4.07D.02 Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors

P4.07D.03 Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC

P4.07D.04 Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC

P4.07E.01 A Revised International Association for the Study of Lung Cancer Grading System: The Inclusion of Invasive Mucinous Adenocarcinomas

P4.07E.02 Genomic Profiling of Pre-invasive and Early-Stage Lung Adenocarcinoma Delineates Gene Signatures of Different Adenocarcinoma Subtypes

P4.07E.03 Real-World Data on Early Lung Cancer in Never-Smokers and Light Smokers-Prevalence, Family History, and Molecular Alterations

P4.07E.04 Pathological Grading of Early-Stage Lung Cancers Through CT-to-PET Translation and Co-Learning Model

P4.07E.05 Insights from Molecular Profiling after Second Lung Surgeries in Early-Stage NSCLC - Recurrence or New Primary Tumor?

P4.07E.06 Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas

P4.07E.07 Spatial Memory B Cells Activation by CXCL13+ Th Cells via the MIF(CD74-CXCR4) Axis may Improve Immunotherapy Efficacy in HER2 Mutant NSCLC

P4.07E.08 Single-Cell TCR Barcoding and RNA Sequencing Illuminate Distinct Tumor-Draining Lymph Node T Cell Responses to Neoadjuvant PD-1 Blockade

P4.07E.10 The Impact of PD-1/PD-L1 Inhibitor on GGN Lesion: An Exploratory and Retrospective Study

P4.07F.01 Real World Characteristics and Distant Metastasis Free Survival of Patients with Early NSCLC Treated with Chemoimmunotherapy

P4.07F.02 Invasiveness Diagnosis by Intraoperative Frozen Section Guides Resection Strategy Amomg ≤2cm Non-Small-Cell Lung Cancer

P4.07F.03 A Cost-Effective Tumor-Informed ctDNA Analysis for MRD Detection in Resected NSCLC With Common Driver Genes

P4.07F.04 Ground Glass Nodules with Scattered or Eccentric Island-Shaped Consolidations may have Poor Outcomes

P4.07F.05 Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection

P4.07F.06 CT-Based Deep Learning Model for Predicting Visceral Pleural Invasion in NSCLCs with Tumor Diameter Less Than 3cm

P4.07G.01 Incidence of and Outcomes of Second Primary Lung Cancer after Resection for Screen-Detected Lung Cancer

P4.07G.02 Prediction of Relapse-free Survival of NSCLC Patients Through Multimodal Data Fusion Using Deep Learning Model

P4.07G.03 Real-World Clinical Outcomes and the Association Between EFS and OS in Early-Stage NSCLC Treated with Primary SBRT

P4.07G.05 Prediction of Quality-of-Life Results after Lung Stereotactic Body Radiotherapy Using Functional Mapping on Gallium-68 Perfusion PET/CT

P4.11D.01 TRITON: Tremelimumab + Durvalumab + Chemotherapy (CT) vs Pembrolizumab + CT in mNSCLC with STK11, KEAP1 and/or KRAS Mutations

P4.11D.011 Evaluating the Impact of Performance Status on Outcomes in Advanced Lung Cancer: A Phase II Clinical Trial

P4.11D.02 Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ≥50%

P4.11D.03 Trial in Progress: Phase 1/2 Study of OBX-115 Engineered Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy in Patients with Advanced Solid Tumors

P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress Update

P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy

P4.11D.06 A Phase II Trial of Restorative Microbiota Therapy with Chemoimmunotherapy in Metastatic Non-Small Cell Lung Cancer

P4.11D.08 Tislelizumab in Combination with Anlotinib as First-Line Treatment for Advanced Pulmonary Sarcomatoid Carcinoma: A Phase II Study

P4.11D.09 Fianlimab-Based Combination Therapies in Patients with Advanced Non-Small Cell Lung Cancer: Trials in Progress Updates

P4.11D.10 A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases

P4.11D.12 Phase 3 Trial of OSE2101 Versus Docetaxel in Patients with Non-Small Cell Lung Cancer & Secondary Resistance to Immunotherapy

P4.11E.01 Real-World First-Line Maintenance Immunotherapy for Nonsquamous Advanced/Metastatic NSCLC without Targetable Mutations

P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study

P4.11E.03 Safety and Efficacy of AL2846 Combined with TQB2450 In NSCLC Patients with Previous PD-(L)1 Inhibitor Treated (NCT06116240)

P4.11E.05 A Phase II, Randomized Trial of Trilaciclib Plus Chemotherapy and Tislelizumab as First-Line Treatment for Advanced SqNSCLC

P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

P4.11E.07 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy for NSCLC

P4.11E.08 Integrated PK/PD Modeling for Uliledlimab, an Anti-CD73 Monoclonal Antibody, In Non-Small Cell Lung Cancer Patients

P4.11E.09 The Efficacy of PD-1/PD-L1 Inhibitors Combined with Chemotherapy and Anti-Angiogenesis Therapy in Driver Gene-Negative NSCLC Brain Metastases

P4.11E.10 Safety and Efficacy of Sintilimab Combined with Anlotinib in Patients with KRAS-Mutant Advanced Non-Small Cell Lung Cancer

P4.11E.11 Dosing Regimen for Acasunlimab (DuoBody-PD-L1x4-1BB) In Combination with Pembrolizumab

P4.11E.12 First Line Camrelizumab for Brain Metastases of NSCLC (CTONG 2003): A Randomized Controlled Trial

P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US

P4.11E.14 Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated with PD-1/PD-L1 Inhibitors

P4.11E.15 Risk Factors for Ir-AEs in Patients with NSCLC Receiving Chemotherapy Combined with a PD-1/PD-L1 Inhibitor or Nivolumab and Ipilimumab

P4.11E.16 Clinical Outcome of HER2-mut NSCLC Treated with First-Line Immunotherapy-Based Regimens versus Chemotherapy/HER2-TKIs

P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade

P4.11E.18 Impact of Prophylactic use of PEG-rhG-CSF on First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancer: A Cohort Study

P4.11E.19 The Effect of COVID-19 On Treatment Outcomes in Non-Small Cell Lung Cancer Patients: A Propensity Score Matched Analysis

P4.11E.23 Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)

P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC

P4.11E.25 NSCLC Immune Hemogram Index (NIHX) A Predictive Score for Immunotherapy Response in PD-L1 Negative Advanced NSCLC

P4.11E.26 A Multicenter Retrospective Study Reveals High MET Expression Associated with Superior Benefit from Immunotherapy in Advanced NSCLC Patients

P4.11E.27 Comparison of Immunotherapy for Metastatic Non-Small Cell Lung Cancer in Real-World Practice: A Japanese Registry Study

P4.11E.28 Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA

P4.14C.01 Trends of Asbestos Lung Content in the General Population

P4.14C.02 Analysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma : A Single Center Retrospective Study

P4.14C.03 Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)

P4.14C.04 Exhaled Breath Analysis for the Early Diagnosis of Malignant Pleural Mesothelioma and the Surveillance of Asbestos-Exposed At-Risk Subjects

P4.14C.05 Incidence of Pseudoprogression and Hyperprogression in Patients with Pleural Mesothelioma Treated with Ipilimumab and Nivolumab

P4.14C.06 Effect of Cytotoxic Chemotherapy Following Ipilimumab Puls Nivolumab Combination Therapy for Malignant Pleural Mesothelioma

P4.14C.07 A Combination of Routine and Novel Immunohistochemical Markers to Improve the Histological Diagnosis of Mesothelioma in Challenging Biopsies

P4.15A.01 Efficacy of Digital Therapeutics for the Perioperative Management in Patients with Lung Cancer: A Randomized Controlled Trial

P4.15B.01 Remote Exercise Program for Patients with Lung Cancer on Immune Checkpoint Inhibitors

P4.15B.02 Cardiopulmonary Rehabilitation Exercises Effectively Improve the Radiation-Induced Cardiopulmonary and Patients' Life Quality

P4.15C.01 Improving Care Coordination to Address Healthcare Inequities in Lung Cancer

P4.15C.02 Palliative Care Impact on Time Toxicity Among Patients with Advanced Lung Cancer at the End of Life

P4.15C.03 Successful Implementation of a Lung Cancer Navigator Workshop: A Cancer Site-Specific Training Program by GO2 For Lung Cancer

P4.15D.01 Beyond Survival: A Pilot Study Analyzing Physician and Patient Perspectives on Lung Cancer Survivorship Care at Weill Cornell Medicine

P4.15D.02 Risk of Osteoporosis and Bone Fracture by Systemic Therapy in Lung Cancer Survivors

P4.15D.03 The Lung Cancer Stigma Communications Assessment Tool: Supporting Engagement with the Lung Cancer Community

P4.15D.04 Association Between Emotional Distress and Immunotherapy Response in Advanced NSCLC (STRESS-LUNG-1): Biomarkers Exploratory Analyses

P4.15E.01 Association Between Dynamic Patient-Reported Outcome-Based Symptom Exacerbation and Postoperative Complication in Lung Cancer

P4.15E.02 Acceptability and Feasibility of Integrating A Chatbot into Routine Lung Cancer Care: Patient and Clinician Perspectives

P4.17C.01 Clinical Trial Enrollment at a Thoracic Oncology Program at a Single-Academic Institution Serving Primarily Underrepresented Patients

P4.17D.01 Incidence Correlation Between Different Diseases and Lung Cancer: A Global Cross-Sectional and Time-series Study

P4.17D.03 Analysis of Lung Cancer Mortality Trends and Factors Impacting Years of Life Lost: A 20-Year Hospital-Based Cohort Study in São Paulo, Brazil.

P4.17D.04 Insights into Lung Cancer During Pregnancy: Analysis of the National Inpatient Database (NIS)

P4.17D.05 Squamous Cell Lung Cancer Still Remains the Most Common Histological Subtype of Lung Cancer in Rural India

P4.17D.06 Pan-Canadian Lung Cancer Observational Study (PALEOS): A Multicentre Ambispective Real-World Database Study in a Publicly Funded Health System

P4.17D.07 Temporal Improvements in Overall Survival in Metastatic Non-Small Cell Lung Cancer in the United States Since 2004

P4.17E.01 Navigating from Target to Treatment: Early Impact of the Lung Precision Oncology Navigation Program (LPOP)

P4.17F.01 Effective EGFR Testing Rates in Advanced Stage NSCLC Patients Treated in Community Oncology Practices: Impact of a Decision Support Program

P4.17F.02 Sociodemographic and Clinical Predictors of Diagnosis of Lung Cancer in the Emergency Department in a Large, Integrated Health System

P4.17F.03 Utilizing AI for Automated Data Entry and Analysis to Pre-Screen Lung Cancer Clinical Trial Candidates

P4.17F.04 Feasibility of Comprehensive Genomic Profiling for Advanced NSCLC in Public Healthcare System - The Hong Kong Experience

P4.17F.05 Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer

P4.17F.06 Review of State Legislation Mandating Biomarker Coverage in Cancer Care